Alirocumab (anti-PCSK9)
Alirocumab (anti-PCSK9) (A2047-GRP)
Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
View Data Sheet
Products
Description
Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
Specifications
| Manufacturer Cat# | A2047 |
|---|
